All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the 2021 ASCO Annual Meeting and the EHA 2021 Virtual Congress, the ALL Hub spoke with Bijal Shah, Moffitt Cancer Center, Tampa, US. We asked, Is the anti-CD19 CAR-T brexu-cel (formerly KTE-X19) safe and effective in B-ALL?
Is the anti-CD19 CAR-T brexu-cel safe and effective in B-ALL?
Shah evaluates safety and efficacy data from the ZUMA-3 study, evaluating brexu-cel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). He focuses on contextualizing these results in comparison with previously approved regimens.
Young adult and pediatric ALL: Current induction regimens and prognostic factors
In a review published in Expert Review of Hematology, Saveria Capria and colleagues discuss the currently available induction treatments for children and adolescents...
What are the main advances in patient care that we are seeing with novel agents for leukemia? ASCO21
During the 2021 ASCO Annual Meeting, the ALL Hub spoke with Jorge Cortes, Augusta University, Augusta, US. We asked, What are the main advances in...
Subscribe to get the best content related to ALL delivered to your inbox